Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. uri icon

authors

  • Mateos, Maria-Victoria
  • Flogegard, Max
  • Bladé, Joan
  • Moreau, Philippe
  • Kaiser, Martin
  • Iida, Shinsuke
  • Laubach, Jacob
  • Magen, Hila
  • Cavo, Michele
  • Hulin, Cyrille
  • White, Darrell
  • Nahi, Hareth
  • De Stefano, Valerio
  • Clemens, Pamela L
  • Masterson, Tara
  • Lantz, Kristen
  • O'Rourke, Lisa
  • Heuck, Christoph
  • Qin, Xiang
  • Parasrampuria, Dolly A
  • Yuan, Zhilong
  • Xu, Steven
  • Legiec, Wojciech
  • Qi, Ming
  • Usmani, Saad Z
  • Grosicki, Sebastian
  • Vorobyev, Vladimir
  • Spicka, Ivan
  • Hungria, Vania
  • Korenkova, Sibirina
  • Bahlis, Nizar

publication date

  • January 1, 2020